This is a multicenter, open-label, phase Ib/II study of YL202 in combination with other anti-tumor therapies to Evaluate the Safety, Tolerability, and Efficacy in Patients with Advanced Solid Tumors
Informed of the study before the start of the study and voluntarily sign their name and date in the informed consent form (ICF)
Able and willing to comply with protocol visits and procedures
Aged between 18 to 75 years
Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1
With prior drug therapy targeting HER3 (including antibodies, antibody-drug conjugates [ADCs]), chimeric antigen receptor T-cell immunotherapy (CAR-T), and other drugs).
Previously intolerant to topoisomerase I inhibitors or ADC therapy composed of topoisomerase I inhibitors.
Are participating in another clinical study, unless it is an observational (non-interventional) clinical study or in the follow-up period of an interventional study.
The washout period from the previous anti-tumor therapy is insufficient before the first dose of the investigational product.